Editorial: Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond

被引：5
|
作者：
Grandi, Eleonora [1 ]
Morotti, Stefano [1 ]
Pueyo, Esther [2 ]
Rodriguez, Blanca [3 ]
机构：
[1] Univ Calif Davis, Dept Pharmacol, Davis, CA 95616 USA
[2] Univ Zaragoza, Aragon Inst Engn Res, Biomed Signal Interpretat & Computat Simulat Grp, IIS Aragon, Zaragoza, Spain
[3] Univ Oxford, Dept Comp Sci, Oxford, England
来源：
FRONTIERS IN PHYSIOLOGY | 2018年 / 9卷
基金：
英国惠康基金;
关键词：
cardiotoxicity; QT interval prolongation; drug-induced arrhythmia; multi-scale modeling; cardiac electrophysiology; TORSADES-DE-POINTES; TRANSMURAL DISPERSION; MODELS; REPOLARIZATION; DRUGS; ELECTROPHYSIOLOGY; CONVERGENCE; SIMULATION; PREDICTION; DYNAMICS;
D O I：
10.3389/fphys.2018.00678
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Rivastigmine and QT interval prolongation
    Inglis, F
    BRITISH JOURNAL OF PSYCHIATRY, 2003, 182 : 549 - 550
  • [22] SYNCOPE AND QT INTERVAL PROLONGATION
    MEZGER, J
    ETTINGER, U
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1990, 132 (46): : 730 - 731
  • [23] The assessment of drug induced QT interval prolongation in healthy subjects:: QTc interval, QT (QTc) dispersion?
    Nemat, S
    Prasad, V
    Oliver, S
    Hedge, A
    Amakye, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 90 - 90
  • [24] Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve
    Vormberge, T
    Hoffmann, M
    Deitermann, M
    Herbold, S
    Himmel, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R128 - R128
  • [25] QT interval prolongation by noncardiovascular drugs: A proposed assessment strategy
    Pourrias, B
    Porsolt, RD
    Lacroix, P
    DRUG DEVELOPMENT RESEARCH, 1999, 47 (02) : 55 - 62
  • [26] Risk factors of QT interval prolongation in Japanese patients with schizophrenia
    Ozeki, Y.
    Aoki, T.
    Fujii, K.
    Kurimoto, N.
    Takahashi, J.
    Ishida, N.
    Narita, M.
    Yamada, N.
    Saitoh, O.
    Horie, M.
    Kunigi, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 149 - 149
  • [27] Lisdexamfetamine-related risk of QT-interval prolongation
    Reactions Weekly, 2024, 2011 (1) : 2 - 2
  • [28] COMBINATION OXALIPLATIN AND DOFETILIDE IS A HIGH RISK FOR QT INTERVAL PROLONGATION
    Antoun, Muhannad
    Moore, Scott R.
    Srivastava, Shaurya
    Pahwa, Rajit
    Jafar, Nagham L.
    Edward, Selwan O.
    Abramovitz, Aaron
    CHEST, 2022, 162 (04) : 794A - 795A
  • [29] A RISK SCORE TO PREDICT QT INTERVAL PROLONGATION IN HOSPITALIZED PATIENTS
    Tisdale, James
    Wroblewski, Heather A.
    Kingery, Joanna R.
    Trujillo, Tate N.
    Overholser, Brian R.
    Kovacs, Richard J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E112 - E112
  • [30] The Half RR Rule: A Poor Rule of Thumb and Not a Risk Assessment Tool for QT Interval Prolongation
    Berling, Ingrid
    Isbister, Geoffrey K.
    ACADEMIC EMERGENCY MEDICINE, 2015, 22 (10) : 1139 - 1144
12345